Texas Capital Bancshares Inc TX Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Texas Capital Bancshares Inc TX increased its holdings in Johnson & Johnson (NYSE:JNJ) by 26.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,268 shares of the company’s stock after purchasing an additional 1,096 shares during the period. Texas Capital Bancshares Inc TX’s holdings in Johnson & Johnson were worth $770,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Innealta Capital LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. MFA Wealth Advisors LLC purchased a new stake in Johnson & Johnson during the second quarter valued at approximately $43,000. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at approximately $44,000. Fairfield Financial Advisors LTD purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $46,000. Finally, Grayhawk Investment Strategies Inc. raised its holdings in Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 20th. TD Securities dropped their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, TD Cowen cut their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Down 0.0 %

Shares of Johnson & Johnson stock opened at $161.37 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market cap of $388.37 billion, a price-to-earnings ratio of 10.06, a PEG ratio of 2.69 and a beta of 0.53. The firm’s 50-day moving average is $162.15 and its two-hundred day moving average is $154.27.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.80 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.